Boehringer Ingelheim: Heart Failure trials
The registry lists 14 Heart Failure studies with Boehringer Ingelheim as lead sponsor. 4 are open to participants now and 9 have results posted.
Phase 3 8No phase 6(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Real-world Study to Describe the Effectiveness and Safety Outcomes of Jardiance in Chinese Patients With Heart Failure and Preserved Ejection FractionNot yet recruitingNCT07047508
- Real-world Comparative Effectiveness and Safety of Jardiance in Chinese Patients With Heart Failure of Reduced Ejection FractionNot yet recruitingNCT07044700
- A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the HeartRecruitingNCT06935370Phase 3
- A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart FailureRecruitingNCT06424288Phase 3
- Emp-Activity: Empagliflozin Functional CapacityCompletedNCT05350202Results posted
- Post Marketing Surveillance (PMS) of JARDIANCE in Chronic Heart Failure (CHF)CompletedNCT05262764Results posted
- Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart FailureCompletedNCT05236673Results posted
- A Study to Test the Effect of Empagliflozin in Patients Who Are in Hospital for Acute Heart FailureCompletedNCT04157751Phase 3Results posted
- This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Reduced Ejection Fraction (HFrEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure SymptomsCompletedNCT03448419Phase 3Results posted
- This Study Tests Empagliflozin in Patients With Chronic Heart Failure With Preserved Ejection Fraction (HFpEF). The Study Looks at How Far Patients Can Walk in 6 Minutes and at Their Heart Failure Symptoms.CompletedNCT03448406Phase 3Results posted
- A Study That Looks at the Function of the Heart in Patients With Heart Failure Who Take EmpagliflozinCompletedNCT03332212Phase 3Results posted
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced)CompletedNCT03057977Phase 3Results posted
- EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved)CompletedNCT03057951Phase 3Results posted
- The Use of Pramipexole and Other Dopamine Agonists and the Risks of Heart Failure and PneumoniaCompletedNCT02236741